The most important trials in cardiology in 2020

Authors: Golukhova E.Z.

Company: Bakoulev National Medical Research Center for Cardiovascular Surgery, Moscow, 121552, Russian Federation

For correspondence:  Sign in or register.

Type:  Editorial article


DOI: https://doi.org/10.24022/1997-3187-2020-14-4-307-312

For citation: Golukhova E.Z. The most important trials in cardiology in 2020. Creative Cardiology. 2020; 14 (4): 307–12 (in Russ.). DOI: 10.24022/ 1997-3187-2020-14-4-307-312

Received / Accepted:  21.12.2020 / 25.12.2020

Keywords: atrial fibrillation heart failure COVID-19

Full text:  

 

Abstract

2020 – was a year of COVID-19 pandemy, so the attention of medical and research world was focused on a new coronavirus infection. However cardiovascular mortality during this year increased ignificantly. While the health encounter, on the contrary, dramatically decreased during the lockdown period. The article is dedicated to the most important questions of 2020, including: treatment tactics in patients with chronic coronary heart disease, atrial fibrillation, anticoagulant therapy in patients with prosthetic valves, the latest approaches in the pharmacotherapy of heart diseases.

References

  1. Mafham M.M., Spata E., Goldacre R. et al. COVID 19 pandemic and admission rates for and management of acute coronary syndromes in England. Lancet. 2020; 396 (10248): 381–9.
  2. Wadhera R., Shen Ch., Gondi S. et al. Cardiovascular deaths during the COVID-19 pandemic in the United States. J. Am. Coll. Cardiol. 2021; 77 (2): 159–69. DOI: 10.1016/j.jacc.2020.10.055
  3. Einstein A., Shaw L., Hirschfeld C. et al. International impact of COVID-19 on the diagnosis of heart disease. J. Am. Coll. Cardiol. 2021; 77 (2): 173–85. DOI: 10.1016/j.jacc.2020.10.054
  4. Harrington R.A., Gibson C.M. Top cardiology trials of 2020 in review. Medscape. December 15, 2020.
  5. Krumholz H.M. What can we learn from the ISCHEMIA Trial? 2020. Thebmjopinion.
  6. Maron D.J., Hochman J.S., Reynolds H.R. et al. Initial invasive or conservative strategy for stable coronary disease. N. Engl. J. Med. 2020; 382: 1395–407.
  7. Spertus J.A., Jones P.G., Maron D.J., O’Brien S.M., Reynolds H.R., Rosenberg I. et al. Health-status outcomes with invasive or conservative care in coronary disease. N. Engl. J. Med. 2020; 382: 1408–19. DOI: 10.1056/NEJMoa1916370
  8. Kirchhof P., Camm A.J., Goette A., Brandes A., Eckardt L., Elvan A. et al. Early rhythm-control therapy in patients with atrial fibrillation. N. Engl. J. Med. 2020; 383: 1305–16. DOI: 10.1056/NEJMoa2019422
  9. Andrade J.G., Wells G.A., Deyell M.W., Bennett M., Essebag V., Champagne J. et al. Cryoablation or drug therapy for initial treatment of atrial fibrillation. N. Engl. J. Med. 2021; 384: 305–15. DOI: 10.1056/NEJMoa2029980
  10. Wazni O.M., Dandamudi G., Sood N., Hoyt R., Tyler J. et al. Cryoballoon ablation as initial therapy for atrial fibrillation. N. Engl. J. Med. 2021; 384: 316–24. DOI: 10.1056/NEJMoa2029554
  11. Guimara~es H.P., Lopes R.D., de Barros e Silva P.G.M., Liporace I.L., Sampaio R.O., Tarasoutchi F. et al. Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. N. Engl. J. Med. 2020. 383: 2117–26. DOI: 10.1056/NEJMoa2029603
  12. Brouwer J., Nijenhuis V.J., Delewi R., Hermanides R.S., Holvoet W., Dubois C.L.F. et al. Aspirin with or without clopidogrel after transcatheter aortic-valve implantation. N. Engl. J. Med. 2020; 383: 1447–57. DOI: 10.1056/NEJMoa2017815
  13. Olivotto I., Oreziak A., Barriales-Villa R., Abraham T.P., Masri A., Garcia-Pavia P. et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORERHCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020; 396: 759–69. DOI: 10.1016/S0140-6736(20)31792-X
  14. Teerlink J.R., Diaz R., Felker G.M., McMurray J.J.V., Metra M., Solomon S.D. et al. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: rationale and design of GALACTIC-HF. J. Am. Coll. Cardiol. Heart Fail. 2020; 8 (4): 329–40.
  15. Tardif J.-C., Kouz S., Waters D.D., Bertrand O.F., Diaz R., Maggioni A.P. Efficacy and safety of low-dose colchicine after myocardial infarction. N. Engl. J. Med. 2019; 381: 2497–505. DOI: 10.1056/NEJMoa1912388
  16. Opstal T.S.J., Hoogeveen R.M., Fiolet A.T.L., Silvis M.J.M., Salem S.H.K., Bax W.A. et al. Colchicine attenuates inflammation beyond the inflammasome in chronic coronary artery disease. A LoDoCo2 Proteomic Substudy. Circulation. 2020; 142: 1996–8. DOI: 10.1161/CIRCULATIONAHA.120.050560
  17. Nidorf S.M., Fiolet A.T., Eikelboom J.W. et al. The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics. Am. Heart J. 2019; 218: 46–56.

About Authors

Elena Z. Golukhova, Dr. Med. Sc., Professor, Academician of Russian Academy of Sciences, Сhief of Chair, Acting Head of Bakоulev National Medical Research Center for Cardiovascular Surgery, Deputy Chief Editor of the Journal, ORCID

Chief Editor

Leo A. Bockeria, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, President of Bakoulev National Medical Research Center for Cardiovascular Surgery